Xcel Acquires Rights for 2 Migraine Drugs

Xcel Pharmaceuticals Inc. said it has acquired U.S. rights for two prescription drugs used to treat migraine headaches.

The San Diego-based company acquired the rights to Migranal Nasal Spray, which is patented until December 2009, and DHE 45 Injection, a standard treatment for migraine, from East Hanover N.J.-based Novartis Pharmaceuticals Corp. Terms of the deal were not disclosed, but Xcel said it raised $22.5 million to help it acquire the rights.